Thus, identifying tumor subtypes in which PEAK1 levels or PEAK1-induced EMT gene signatures are elevated may facilitate the selection of patients that will respond positively to anti-TGFβ treatment regimens. This evidence concerns the gene TGFB1 and neoplasm.